Sientra to Report Fourth Quarter and Full Year 2021 Financial Results on March 23, 2022

Rhea-AI Summary

Sientra, Inc. (NASDAQ: SIEN), a medical aesthetics company, will release its financial results for Q4 and the full year of 2021 on March 23, 2022, after market close. A conference call is scheduled for the same day at 4:30 PM ET, where they will discuss the results. Investors can access the call via dial-in numbers or a live webcast on the investor relations section of their website. Sientra focuses on providing innovative products for plastic surgery, including FDA-approved breast implants and advanced surgical tools.

Positive

• Scheduled release of financial results may indicate transparency and engagement with investors.
• Innovative product portfolio includes FDA-approved fifth-generation breast implants and advanced surgical tools.

Negative

• None.

SANTA BARBARA, Calif., March 09, 2022 (GLOBE NEWSWIRE) -- Sientra, Inc. (NASDAQ: SIEN) (“Sientra” or the “Company”), a medical aesthetics company focused on enhancing lives by advancing the art of plastic surgery, today announced that it will release financial results for the fourth quarter and full year of 2021 after the close of trading on Wednesday, March 23, 2022. Sientra will host a conference call to discuss financial results the same day at 4:30 p.m. Eastern Time.

The dial-in numbers are (844) 464-3933 for domestic callers and (765) 507-2612 for international callers. The conference ID is 4862817.

A live webcast of the conference call will be available on the Investor Relations section of the Company's website at www.sientra.com. The webcast will be archived on the website following the completion of the call.  

About Sientra
Headquartered in Santa Barbara, California, Sientra is a medical aesthetics company exclusively focused on plastic surgery. The Company mission is to offer proprietary innovations and unparalleled partnerships that radically advance how plastic surgeons think, work and care for their patients. Sientra has developed a broad portfolio of products with technologically differentiated characteristics, supported by independent laboratory testing and strong clinical trial outcomes. The Company’s product portfolio includes its Sientra round and shaped breast implants, the first fifth generation breast implants approved by the FDA for sale in the United States, its ground-breaking Allox2® breast tissue expander with patented dual-port and integral drain technology, the AuraGen fat grafting system, and BIOCORNEUM®, the #1 performing, preferred and recommended scar gel of plastic surgeons(*).

Sientra uses its investor relations website to publish important information about the Company, including information that may be deemed material to investors. Financial and other information about Sientra is routinely posted and is accessible on the Company’s investor relations website at www.sientra.com.

^(*) Data on file

Investor Relations Contact
Leigh Salvo
ir@sientra.com

FAQ

When will Sientra release its 2021 financial results?

Sientra will release its financial results for 2021 on March 23, 2022.

What time is Sientra's conference call for Q4 results?

The conference call is scheduled for 4:30 PM ET on March 23, 2022.

How can I listen to Sientra's financial results conference call?

You can listen to the conference call via dial-in numbers or through a live webcast on Sientra's investor relations website.

What is Sientra's focus in the medical aesthetics market?

Sientra focuses on enhancing lives through innovative products in plastic surgery.